Primary autoimmune neutropenia (AIN) is caused by granulocyte-specific
autoantibodies and occurs predominantly in infancy. Clinical presenta
tion and diagnosis have not been well established, resulting in burden
ing diagnostic investigations and unnecessary treatment with granulocy
te colony-stimulating factor (G-CSF). In the present study, clinical,
laboratory, and immunologic data of 240 infants with primary AIN were
evaluated. Suspected association with parvovirus B19 infection was inv
estigated using serologic and DMA-based methods. Primary AIN was mainl
y diagnosed at the age of 5 to 15 months but was observed as early as
day 33 of life. In 90% of the cases, AIN was associated with benign in
fections despite severe neutropenia. Spontaneous remission, shown by 9
5% of the patients, usually occurred within 7 to 24 months. Autoantibo
dies in the patient's sera were not always present, and screening had
to be repeated several times until antibody detection succeeded. About
35% of the autoantibodies showed preferential binding to granulocytes
from NA1 and NA2 homozygous donors. Bone marrow was typically normoce
llular or hypercellular, with a variably diminished number of segmente
d granulocytes. A significant association with parvovirus B19 infectio
n was not found. Symptomatic treatment with antibiotics was sufficient
in most patients. Eighty-nine percent of the patients received antibi
otics (cotrimoxazole) for prophylaxis of infections. For severe infect
ions or for surgical preparation, G-CSF, corticosteroids, and intraven
ous IgG were administered, resulting in increased neutrophil counts in
100%, 75%, and 50% of the patients treated, respectively. In combinat
ion with the detection of granulocyte-specific antibodies, the typical
clinical picture allowed diagnosis of AIN without burdening investiga
tions. Treatment with G-CSF was found to be a reliable alternative to
temporarily increase the neutrophil count. (C) 1998 by The American So
ciety of Hematology.